Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.
see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.

The Company has developed a body of patents covering

• anti-viral,
• anti-inflammatory
• and anti-bacterial applications.

AWARDS

GlaxoSmithKline
Drug Discovery and Development Award
September 2002

to our collaborator, Dr. Min Lu
Cornell Weill School of Medicine
for Structural Biology Studies to Determine How Doxovir™ Inhibits HIV

SEE ALSO

Our Company

Management and Board of Directors